Delivery Order SPE2DB24D2205-SPE2DB25FEGBJ
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,786.46 on July 18, 2025, for the supply of Lyrica 50 mg capsules (90-count units). This contract was awarded on a firm fixed price basis with no set-aside designation, indicating competitive award conditions. The order is scheduled for completion by July 21, 2025, and is being funded through the Medical Supply Chain division of the Department of...
- The Defense Logistics Agency awarded a delivery order valued at $4,746.84 to AmerisourceBergen Drug Corp for the supply of Lyrica 100 mg capsules (90-count units) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Lyrica 300 mg capsules (90-count). The contract carries a ceiling value of $1,179.94 under firm fixed pricing terms, with an ultimate completion date of July 25, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract issued under a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,550.74 for 90 capsules of Lyrica 100 mg on August 18, 2025, with an ultimate completion date of August 19, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,985.20 delivery order to AmerisourceBergen Drug Corp for 90 units of Lyrica 75 mg capsules, effective July 28, 2025, with completion scheduled for July 29, 2025. This is a firm fixed-price, non-set-aside contract supporting federal pharmaceutical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor to military and veteran healthcare systems and is registered in the System for...
- The Defense Logistics Agency awarded a delivery order valued at $1,179.94 to AmerisourceBergen Drug Corp for 90-count bottles of Lyrica 300 mg capsules. This award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its Corporate Office division. The...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,367.20 firm fixed-price delivery order is for the supply of Lyrica 100 mg capsules. The contract has an ultimate completion date of February 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- The Defense Logistics Agency awarded a delivery order valued at $7,170.96 to AmerisourceBergen Drug Corp for the supply of Lyrica 100 mg capsules (90-count units) under a firm fixed price contract. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this contract at its corporate office location, leveraging its extensive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,851.66 to AmerisourceBergen Drug Corp for the supply of Lyrica 200 mg capsules (90-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Lyrica 100 mg capsules (90 count) with a contract value of $4,272.77. This is a firm fixed price delivery order with an ultimate completion date of August 19, 2025, and represents a non-competitive set-aside award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGBJDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $2,958.95 delivery order from the Defense Logistics Agency (DLA) for 90 capsules of Lyrica 100 mg on August 11, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside contract award utilizes firm fixed-price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The Lyrica pharmaceutical product serves neurological treatment applications within the federal military healthcare system. This award is issued under DLA's Medical Supply Chain operations, which procures comprehensive pharmaceutical and medical supply products for Defense Health Agency customers, U.S. Coast Guard, and other federal healthcare systems. AmerisourceBergen's prime indefinite delivery vehicle enables the company to supply a broad range of brand-name and generic medications, vaccines, medical devices, and specialty pharmaceuticals to support military healthcare requirements globally. The company's demonstrated capability to compete successfully for federal medical procurement, combined with its extensive experience fulfilling varied therapeutic pharmaceutical needs, positions it as a critical vendor within the federal healthcare procurement ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 8/11/25 |